Donor CMV serostatus not predictive of relapse in D-/R- pediatric HCT

Biol Blood Marrow Transplant. 2009 Jun;15(6):758-60. doi: 10.1016/j.bbmt.2009.03.025.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acyclovir / administration & dosage
  • Acyclovir / therapeutic use
  • Adolescent
  • Adult
  • Antibodies, Viral / blood
  • Antigens, Viral / blood
  • Antiviral Agents / administration & dosage
  • Antiviral Agents / therapeutic use
  • Child
  • Child, Preschool
  • Cytomegalovirus / immunology
  • Cytomegalovirus / physiology
  • Cytomegalovirus Infections / drug therapy
  • Cytomegalovirus Infections / epidemiology*
  • Cytomegalovirus Infections / prevention & control
  • Cytomegalovirus Infections / transmission
  • Disease-Free Survival
  • Ethnicity / statistics & numerical data
  • Female
  • Foscarnet / administration & dosage
  • Foscarnet / therapeutic use
  • Ganciclovir / administration & dosage
  • Ganciclovir / therapeutic use
  • Graft vs Host Disease / epidemiology
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Humans
  • Infant
  • Infant, Newborn
  • Living Donors
  • Male
  • Middle Aged
  • Myeloablative Agonists / adverse effects
  • Postoperative Complications / epidemiology*
  • Premedication
  • Proportional Hazards Models
  • Recurrence
  • Tissue Donors*
  • Transplantation Conditioning / adverse effects
  • Transplantation, Homologous / adverse effects
  • Virus Activation
  • Young Adult

Substances

  • Antibodies, Viral
  • Antigens, Viral
  • Antiviral Agents
  • Myeloablative Agonists
  • Foscarnet
  • Ganciclovir
  • Acyclovir